Supreme Court Denies Bhagat’s Nutritional Patent Petition: Key Insights for IP & R&D Teams
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Urvashi Bhagat v. United States Patent and Trademark Office |
| Case Number | 24-950 (U.S. Supreme Court) |
| Court | U.S. Supreme Court, Appeal from DC Jurisdiction |
| Duration | Jan 2025 – Apr 2025 90 days |
| Outcome | Petition Denied – USPTO Determination Upheld |
| Patents at Issue | |
| Accused Products | Optimized Nutritional Formulations, Methods for Selection of Tailored Diets Therefrom, and Methods of Use Thereof |
Case Overview
The Parties
⚖️ Plaintiff
Individual inventor asserting rights over a nutritional science patent application. No corporate affiliation is listed in the case record, suggesting an independent inventor.
🛡️ Defendant
Federal agency responsible for examining and granting U.S. patents. Represented by D. John Sauer through the Office of the Solicitor General, United States Department of Justice.
Patents at Issue
This case centered on a single patent application covering systems and methods for customizing nutritional products or dietary regimens:
- • US20130261183A1 — Optimized nutritional formulations, methods for selecting tailored diets, and associated methods of use
Developing personalized nutrition products?
Check if your technology might infringe related patents or face patentability challenges.
The Verdict & Legal Analysis
Outcome
The Supreme Court denied the petition in Case No. 24-950, effectively leaving intact the USPTO’s prior determination regarding patentability. The case was terminated on the basis of petition dismissed, with no damages awarded, no injunctive relief issued, and no remand ordered.
Key Legal Issues
The underlying USPTO challenge to the patent application likely rested on patentability grounds such as § 101 Subject Matter Eligibility (for methods involving algorithmic selection processes) or § 102/103 Novelty and Obviousness due to pre-existing literature. The Supreme Court’s denial of certiorari leaves this reasoning undisturbed.
Drafting patents in nutritional science?
Learn from this case. Focus on concrete, application-specific limitations to strengthen claims.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the personalized nutrition and digital health space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patents in personalized nutrition and digital health
- See key players in the nutritional science patent landscape
- Understand claim drafting strategies to overcome § 101 challenges
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Personalized nutrition method claims (§ 101)
High Scrutiny Area
Biotech & digital health method claims
Limited Precedent
Denial doesn’t set precedent, but reinforces USPTO.
✅ Key Takeaways
For Patent Attorneys
Certiorari denial leaves USPTO patentability rejections in nutritional method patents undisturbed at the Supreme Court level.
Explore § 101 precedents →§ 101 subject matter eligibility remains the primary vulnerability for personalized nutrition and tailored diet method claims.
Review recent § 101 cases →For R&D Teams
FTO clearance for nutritional formulation platforms must extend to pending applications, not only granted patents.
Start FTO analysis for my product →Design-around strategies should focus on structural differentiation and non-abstract method steps.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.